English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 146.27%
Price change 2019 → 2020: 22.42%
Price change 2020 → 2021: -35.15%
Price change 2021 → 2022: -30.99%
Price change 2022 → 2023: -57.08%
Price change 2023 → 2024: -14.69%
Price change 2024 → 2025: 81.87%
Price change 2025 → 2026: 8.80%
Price change 2026 (year to date): 7.38%
Financial growth
Revenue CAGR (8 years): -6.78%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Negative or zero equity.
P/E (Price/Earnings)
P/E ratio: -6.01
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 21.08% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ALTHE.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Theraclion S.A. | – | – | +12.1 % | 🔒 |
| Klea Holding | 14.0 | 0.20 | +5.2 % | – |
| Fermentalg | – | 0.20 | +38.5 % | – |
| Adocia S.A. | – | 5.97 | +18.8 % | – |
| Novacyt S.A. | – | 0.45 | +28.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Theraclion S.A. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 829,456 | -4.4 m | -524.9 % | n/a |
| 2021 | 1.7 m | -4.2 m | -253.9 % | +99.1 % |
| 2022 | 1.4 m | -5.5 m | -401.8 % | -16.6 % |
| 2023 | 2.0 m | -4.1 m | -201.7 % | +47.5 % |
| 2024 | 925,334 | -6.4 m | -693.6 % | -54.5 % |
| 2025 | 1.3 m | -6.3 m | -479.8 % | +42.9 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Theraclion S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 2.5 m | 2.5 m | 7.8 m | 4.2 m | 3.4 m |
| Total Debt | 2.4 m | 2.5 m | 2.0 m | 1.3 m | 5.1 m |
| Net Debt | -99,000 | 21,143 | -5.9 m | -2.9 m | 3.2 m |
| Equity | -1.3 m | 544,866 | 5.6 m | -114 | -2.6 m |
| Total assets | 11.8 m | 13.9 m | 18.7 m | 11.5 m | 12.5 m |
| Operating cash flow | -3.9 m | -5.3 m | -2.5 m | -2.9 m | -7.2 m |
| Investments (capex) | 148,220 | 322,676 | 112,294 | 102,000 | 0 |
| Free cash-flow | -4.0 m | -5.6 m | -2.6 m | -3.0 m | -7.2 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Theraclion S.A. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Theraclion S.A. | 57.8 m | n/a | -479.8 % |
| Implanet S.A. ALIMP.PA | 23.9 m | n/a | -35.1 % |
| Diagnostic Medical Systems S.A. ALDMS.PA | 26.3 m | n/a | -0.3 % |
| Novacyt S.A. ALNOV.PA | 35.7 m | n/a | -114.2 % |
| Ikonisys S.A. ALIKO.PA | 25.1 m | n/a | -302.8 % |
| Valerio Therapeutics S.A. ALVIO.PA | 257 m | n/a | -190.4 % |
| Nicox S.A. ALCOX.PA | 33.0 m | n/a | -14.4 % |
| Advicenne S.A. ALDVI.PA | 10.5 m | n/a | -158.7 % |
| Bluelinea S.A. ALBLU.PA | 2.6 m | n/a | -14.5 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Theraclion S.A.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Stock splits
| Date | Operation |
|---|---|
| 26/07/2016 | split: 131 shares for 125 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Theraclion S.A.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Theraclion S.A.
What is the Theraclion S.A. share price?
Latest recorded price: 0.701 EUR on 06/11/2026, for a market cap of 57.7 m USD.
What is the revenue of Theraclion S.A.?
1.3 m USD for fiscal year 2025, with net income of -6.3 m USD (net margin -479.8 %).
Is Theraclion S.A. stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR0010120402) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Theraclion S.A. have?
28 full-time employees according to the latest published profile.
Who runs Theraclion S.A.?
Martin Deterre is the company's chief executive.